MAZE- Maze Therapeutics, Inc.

Trade Summary

1 week ago, Bernstein Harold, serving as President, R&D & CMO at Maze Therapeutics, Inc. (MAZE), sold 10,295 shares at $26.24 per share, for a total transaction value of $270,110.79. Following this transaction, Bernstein Harold now holds 9,705 shares of MAZE.

This sale represents a 51.48% decrease in Bernstein Harold's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, September 2, 2026 and publicly disclosed via SEC Form 4 filing on Friday, September 4, 2026 at 4:22 PM ET, 2 days after the trade was made.

Maze Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.